Skip to main content
Erschienen in: Drug Safety 10/2007

01.10.2007 | Original Research Article

Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases The Notoriety Bias

verfasst von: Dr Antoine Pariente, Fleur Gregoire, Annie Fourrier-Reglat, Françoise Haramburu, Nicholas Moore

Erschienen in: Drug Safety | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Background: Disproportionality analysis of spontaneous reporting is increasingly used, but it may be influenced in unknown ways by safety alerts (notoriety bias).
Objective: To explore the consequences of safety alerts on reporting disproportionality.
Methods: Within the French national pharmacovigilance database, disproportionality of reporting was tested, using the reporting odds ratio (ROR) and its 95% confidence interval, before and after four safety alerts: valvulopathies with pergolide; tuberculosis with infliximab; strokes with atypical antipsychotics; and rhabdomyolysis with HMG-CoA reductase inhibitors (statins) [after cerivastatin withdrawal].
Results: No cases of valvulopathy were reported in association with pergolide before the safety alert and 63 cases were reported after the alert, (ROR 9400; 95% CI4300, 20 000), of which five had occurred before the alert. Twenty-five reports mentioned rhabdomyolysis associated with statins (not including cerivastatin) before the safety alert (ROR 5.8; 95% CI 3.8, 9.0), and 63 did so after the alert (ROR 9.4; 95% CI 7.0, 13.0). Approximately 280 cases involving cerivastatin were reported after its withdrawal. There were two reports of tuberculosis associated with infliximab before the alert (ROR 1500; 95% CI 130, 18 000) and seven after the alert (ROR 430; 95% CI 110, 1700). There was one report of a stroke in association with atypical antipsychotic treatment before the safety alert (ROR 0.10; 95% CI 0.01, 0.63) and 16 after the alert (ROR 1.10; 95% CI 0.70, 1.90). After excluding events involving treatment with anticoagulant agents, the RORs for stroke in association with atypical antipsychotic treatment were 0.14 (95% CI 0.02, 1.00) before the alert and 2.0 (95% CI 1.2, 3.4) after the alert.
Conclusion: Disproportionality in spontaneous reporting databases increases after a safety alert because of increased reporting of the event of interest, including reports of such events that occurred before the alert. This may overflow to increased reporting of the event in association with other drugs.
Literatur
1.
Zurück zum Zitat Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4): 315–21PubMedCrossRef Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4): 315–21PubMedCrossRef
2.
Zurück zum Zitat Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10(6): 483–6PubMedCrossRef Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10(6): 483–6PubMedCrossRef
3.
Zurück zum Zitat Roux E, Thiessard F, Fourrier A, et al. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed 2005; 9(4): 518–27PubMedCrossRef Roux E, Thiessard F, Fourrier A, et al. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed 2005; 9(4): 518–27PubMedCrossRef
4.
Zurück zum Zitat van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11(1): 3–10PubMedCrossRef van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11(1): 3–10PubMedCrossRef
5.
Zurück zum Zitat Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5(6): 363–75PubMedCrossRef Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5(6): 363–75PubMedCrossRef
6.
Zurück zum Zitat Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44(5): 513–8PubMedCrossRef Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44(5): 513–8PubMedCrossRef
7.
Zurück zum Zitat Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13(8): 519–23PubMedCrossRef Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13(8): 519–23PubMedCrossRef
8.
Zurück zum Zitat Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12(4): 271–81PubMedCrossRef Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12(4): 271–81PubMedCrossRef
9.
Zurück zum Zitat Hauben M, Reich L, Van Puijenbroek EP, et al. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol 2006; 62(11): 967–70PubMedCrossRef Hauben M, Reich L, Van Puijenbroek EP, et al. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol 2006; 62(11): 967–70PubMedCrossRef
10.
Zurück zum Zitat Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16(4): 359–65PubMedCrossRef Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16(4): 359–65PubMedCrossRef
11.
Zurück zum Zitat Strom LB. Pharmacoepidemiology. 4th ed. Chichester: Wiley, 2005 Strom LB. Pharmacoepidemiology. 4th ed. Chichester: Wiley, 2005
12.
Zurück zum Zitat van Puijenbroek EP, van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001; 52(5): 579–86PubMedCrossRef van Puijenbroek EP, van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001; 52(5): 579–86PubMedCrossRef
13.
Zurück zum Zitat Begaud B. Dictionary of pharmacoepidemiology. Chichester: John Wiley & sons, 2000CrossRef Begaud B. Dictionary of pharmacoepidemiology. Chichester: John Wiley & sons, 2000CrossRef
18.
Zurück zum Zitat Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64(2): 134–43PubMedCrossRef Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64(2): 134–43PubMedCrossRef
19.
Zurück zum Zitat Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170(9): 1395PubMed Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170(9): 1395PubMed
20.
Zurück zum Zitat Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2(8463): 1056–8 Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2(8463): 1056–8
21.
Zurück zum Zitat Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation [in French]. Therapie 1995; 50(6): 557–62PubMed Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation [in French]. Therapie 1995; 50(6): 557–62PubMed
22.
Zurück zum Zitat Kramer M. Clinical epidemiology and biostatistics. Berlin: Springer Verlag, 1988CrossRef Kramer M. Clinical epidemiology and biostatistics. Berlin: Springer Verlag, 1988CrossRef
23.
Zurück zum Zitat Griffin JP, Weber JC. Voluntary systems of adverse reaction reporting — part I. Adverse Drug React Acute Poisoning Rev 1985; 4(4): 213–30PubMed Griffin JP, Weber JC. Voluntary systems of adverse reaction reporting — part I. Adverse Drug React Acute Poisoning Rev 1985; 4(4): 213–30PubMed
Metadaten
Titel
Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases The Notoriety Bias
verfasst von
Dr Antoine Pariente
Fleur Gregoire
Annie Fourrier-Reglat
Françoise Haramburu
Nicholas Moore
Publikationsdatum
01.10.2007
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 10/2007
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730100-00007

Weitere Artikel der Ausgabe 10/2007

Drug Safety 10/2007 Zur Ausgabe